Recent Updates
Recently added Catalysts

UX003

Phase 3

MPS 7 | Small molecule | Rare Disease |Ultragenyx Pharmaceutical Inc.|Last Updated: Jul 30, 2020

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMC
Total Trials1
Total Enrollment12

FDA Designations

No designations recorded

Clinical trial landscape

UX003 · 4 trials · 6 indications

Phase 3 2Phase 2 1Phase 1 1
NCT02432144A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)Sly Syndrome
COMPLETED12 Analytics
NCT02230566A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)MPS 7
COMPLETED12 Analytics
PHASE3COMPLETED
A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)
Sly SyndromeUnlock trial analytics
PHASE3COMPLETED
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
MPS 7Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
From first dose of study drug until 30 days after the last dose of study drug. Mean duration of UX003 treatment was 100.5 weeks.

An adverse event (AE) is defined as any untoward medical occurrence, whether or not considered drug related. A serious AE is an AE that at any dose, results in any of the following outcomes: death; a life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly/birth defect; or is an important medical event. AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), Grade 5 (death). TEAEs were defined as reported AEs with onset during the treatment.

European Union (EU) and Rest of World: Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate (DS) at UX003 Treatment Week 24
Baseline (defined as the average of all assessments prior to or on the date of cross-over to active treatment with UX003) to 24 weeks of UX003 study drug treatment

Baseline was defined as the average of all assessments prior to or on the date of cross-over to active treatment with UX003. (This provides the valid assessment, as placebo effect was subtracted from the treatment effect estimate providing a more conservative assessment of the true treatment effect.) Percent change from baseline in uGAG DS was analyzed by generalized estimating equation (GEE) modeling based on observed data. The GEE model included included baseline value, and the UX003 treatment week as a categorical variable. The covariance structure within subjects was assumed to be exchangeable. In the United States (US), this was considered a secondary outcome measure. Per guidance from the Food and Drug Administration (FDA), no primary efficacy variable was declared in the US. Efficacy was to be based on the totality of the clinical data on a per participant basis.

Percent Change From Baseline in uGAG Excretion (LC-MS/MS-DS) at Week 48
Baseline (Week 0), Week 48

Liquid chromatography-mass spectrometry/mass spectrometry-dermatan sulfate (LS-MS/MS-DS) method. For the participant previously treated with UX003 under an eIND, percent change from initial baseline was used.

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEs
From first dose of study drug until 30 days after the last dose of study drug. Mean (SD) treatment duration was 98.11 (29.02) weeks

Adverse event (AE): any untoward medical occurrence in a participant, whether or not considered drug related. Serious AE (SAE): an AE or suspected adverse reaction that at any dose results in any of the following outcomes: death; a life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly/birth defect. Other important medical events may also, in the opinion of the Investigator, be considered SAEs. An AE was considered a TEAE if it occurred on or after the first dose, and was not present prior to the first dose, or it was present at the first dose but increased in severity during the study. Events recorded as either possibly, probably, or definitely related to treatment were categorized as related. AE severity was graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 4.03.

Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate
Baseline, Week 14, Week 22, Week 30, Week 38, Week 72, and end of study (up to Week 132)

Percentage change from baseline in the concentration of uGAGs normalized to the urinary creatinine concentration as measured by liquid chromatography-mass spectrometry/mass spectrometry-dermatan sulfate.

Percentage Change From Baseline in uGAG Chondroitin Sulfate
Baseline, Week 14, Week 22, Week 30, Week 38, Week 72, and end of study (up to Week 132)

Percentage change from baseline in the concentration of uGAGs normalized to the urinary creatinine concentration as measured by liquid chromatography-mass spectrometry/mass spectrometry-chondroitin sulfate.

Number of Participants With Any ≥ 50% Decrease in uGAG
up to Week 132

Participants with a ≥ 50% decrease in the concentration of uGAGs normalized to the urinary creatinine concentration as measured by liquid chromatography-mass spectrometry/mass spectrometry-dermatan sulfate or chondroitin sulfate.

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Study/Treatment Discontinuations
Up to 242 weeks + 30 days. SAEs were recorded beginning at the time the subject signed the informed consent form through 30 days following the last study visit. Non-serious AEs were recorded from the time of informed consent through the last study visit.

Adverse Event (AE): any untoward medical occurrence in a subject, whether or not considered drug related. SAE: an AE or suspected adverse reaction that at any dose results in any of the following outcomes: death; a life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly/birth defect. Other important medical events may also, in the opinion of the Investigator, be considered SAEs. An AE was considered a TEAE if it occurred on or after the first dose, and was not present prior to the first dose, or it was present at the first dose but increased in severity during the study. Events recorded as either possibly, probably, or definitely related to treatment were categorized as related. AE severity was graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 4.03.

Secondary Endpoints

Percent Change From Baseline Over Time in Urinary Glycosaminoglycan (uGAG) Excretion (Liquid Chromatography-Tandem Mass Spectrometry, Dermatan Sulfate)
Baseline (prior to the first dose of study drug in UX003-CL301), Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144
Multi-Domain Responder Index (MDRI) Score at UX003 Treatment Week 24
Baseline (defined as the last assessment prior to or on the date of cross-over to active treatment with UX003) to 24 weeks of UX003 study drug treatment
Change From Baseline in 6-Minute Walk Test (6MWT) at UX003 Treatment Week 24
Baseline (defined as the last assessment prior to or on the date of cross-over to active treatment with UX003) to 24 weeks of UX003 study drug treatment
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
UX003EXPERIMENTAL4 mg/kg UX003 every other week (QOW)
Group A: 4 mg/kg UX003EXPERIMENTAL4 mg/kg UX003 QOW through Week 46
Group B: 8 Weeks Placebo then 4 mg/kg UX003EXPERIMENTALPlacebo QOW for the first 8 weeks followed by 4 mg/kg UX003 QOW through Week 46
Group C: 16 Weeks Placebo then 4 mg/kg UX003EXPERIMENTALPlacebo QOW for the first 16 weeks followed by 4 mg/kg UX003 QOW through Week 46
Group D: 24 Weeks Placebo then 4 mg/kg UX003EXPERIMENTALPlacebo QOW for the first 24 weeks followed by 4 mg/kg UX003 QOW through Week 46

Interventions

NameTypeDescription
UX003DRUGsolution for intravenous (IV) infusion
PlaceboOTHERPlacebo consisting of the UX003 formulation buffer (without rhGUS)
Unlock Study Design Details

Eligibility Criteria

Age Range5 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites7

Inclusion Criteria: * Confirmed diagnosis of MPS 7 based on leukocyte or fibroblast glucuronidase enzyme assay or genetic testing. * Willing and able to provide written, signed informed consent or, in the case of subjects under the age of 18 (or 16 years, depending on the region), provide written a...

Countries:United StatesBrazilMexicoPortugalSpainUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about UX003

What is UX003 used for?

UX003 is an investigational enzyme replacement therapy being developed for Sly Syndrome, also known as Mucopolysaccharidosis Type 7 (MPS 7) or MPS VII. It is designed to treat patients with this rare lysosomal storage disease, which is caused by a deficiency of the enzyme beta-glucuronidase.

Who makes UX003?

UX003 is being developed by Ultragenyx Pharmaceutical Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol RARE. The company is focused on developing treatments for rare and ultra-rare diseases.

What phase is UX003 in?

UX003 has completed Phase 3 clinical trials for the treatment of Mucopolysaccharidosis Type 7 (MPS 7), also known as Sly Syndrome. The drug is still investigational and has not been approved by regulatory authorities. It remains in clinical development.

What clinical trials has UX003 been in?

UX003 has been studied in several completed clinical trials, including NCT01856218, a Phase 1/2 study in the United Kingdom; NCT02230566, a Phase 3 study in the United States; NCT02418455, a Phase 2 study in patients under 5 years old; and NCT02432144, a Phase 3 study conducted in multiple countries.

How does UX003 work?

UX003 is a recombinant human beta-glucuronidase (rhGUS) enzyme replacement therapy. It works by providing the missing or deficient beta-glucuronidase enzyme to patients with Mucopolysaccharidosis Type 7 (MPS 7), helping to break down accumulated glycosaminoglycans in the body.

Is UX003 the same as rhGUS?

Yes, UX003 is also known as recombinant human beta-glucuronidase (rhGUS). In clinical trial records, it is referred to as UX003 Recombinant Human Beta-glucuronidase or rhGUS, and it is being studied as an enzyme replacement therapy for Mucopolysaccharidosis Type 7.